06.03.2025 |

BioStock interview with CEO John Glasspool on VMX-C001 at BioCapital Europe

Related items

NewsVarmX receives IND approval for Phase 3 trial of VMX-C001 in Urgent Surgery
Enables initiation of global EquilibriX-S trial later this year Critical milestone in development of novel bypass agent to restore coagulation,…
Management Team, NewsBioStock interview with CEO John Glasspool on VMX-C001 at BioCapital Europe